Drug

Flutamide

In clinical development

Emerging researchLate-stage development

Also known as 4'-nitro-3'-trifluoromethylisobutyranilide, Eulexin, FTA, NFBA+5 more

4'-nitro-3'-trifluoromethylisobutyranilide, Eulexin, FTA, NFBA, Niftolid, Niftolide, Flutamid, Flutamida, Flutamidum.

RxNorm4508 ChEMBLCHEMBL806UNII76W6J0943E

Research papers

Active clinical trials

Latest activity

beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation (PREDICT-RT*)

Clinical trial2026-06-25Results expected Q4 2033 · ClinicalTrials.gov

Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification and Intensification Clinical Trial Evaluation (GUIDANCE)

Clinical trial2026-06-25Results expected Q4 2026 · ClinicalTrials.gov

A Phase III Prospective Randomized Trial of Dose-Escalated Radiotherapy With or Without Short-Term Androgen Deprivation Therapy for Patients With Intermediate-Risk Prostate Cancer

Clinical trial2026-03-06Results posted · ClinicalTrials.gov

A Randomized Study of Finite Androgen Ablation vs. Finite Androgen Ablation in Combination With Abiraterone Acetate and Prednisone in Patients With Prostate Cancer Who Have PSA Progression After Prostatectomy and/or Radiotherapy

Clinical trial2026-02-20Results expected Q1 2027 · ClinicalTrials.gov

Phase II-III Trial of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prostatectomy With or Without Adjuvant Docetaxel

Clinical trial2025-10-31Completed · ClinicalTrials.gov

Randomized Trial Assessing Induction of Double Strand Breaks With Androgen Receptor Partial Agonist in Patients on Androgen Suppression

Clinical trial2025-10-16Results posted · ClinicalTrials.gov

Ability of Androgen-receptor Blockade to Normalize Progesterone-induced Augmentation of Gonadotropin Secretion in PCOS (CRM010)

Clinical trial2025-10-01Primary completion · ClinicalTrials.gov

Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer

Clinical trial2025-09-11Results expected Q2 2028 · ClinicalTrials.gov

An Open, Randomized, Long-Term Clinical Trial of Flutamide, Testolactone, and Reduced Hydrocortisone Dose vs. Conventional Treatment of Children With Congenital Adrenal Hyperplasia

Clinical trial2025-06-12Results posted · ClinicalTrials.gov

Androgen Excess as a Cause for Adipogenic Dysfunction in PCOS Women

Clinical trial2025-01-10Results posted · ClinicalTrials.gov

A Randomized Phase IV Study Comparing Enzalutamide Versus Flutamide in Castration-resistant Prostate Cancer (CRPC) Patients Who Have Failed Combined Androgen Blockade Therapy With Bicalutamide Plus Androgen Deprivation Therapy (ADT)

Clinical trial2024-12-09Results posted · ClinicalTrials.gov

Radiotherapy and short-term androgen deprivation for localized prostate cancer.

Research2011-07-01The New England journal of medicine

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name

Flutamide

Aliases & brands

4'-nitro-3'-trifluoromethylisobutyranilideEulexinFTANFBANiftolidNiftolideFlutamidFlutamidaFlutamidum

RxNorm CUI

4508

ChEMBL ID

CHEMBL806

UNII

76W6J0943E

Clinical trials

54 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme

CLINICALTRIALS.GOV · LIVE REGISTRY

registered trials across all phases

LATEST COMPLETION 2025

Active studies

Recruiting

Late-stage (III+)

Completed

Discontinued

PHASE DISTRIBUTIONn = 54

Early Phase 12Phase 14Phase 216Phase 2 / 32Phase 324Phase 43Phase N / A3

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

The Impact of Continuous Versus Intermittent Androgen Deprivation Therapy on Bone Mineral Density Change in Prostate Cancer Patients: A Multicenter, Randomized Clinical Trial

Unknown statusPH IVWonju Severance Christian Hospitaln=1642022

CompletedPH IVAstellas Pharma Incn=2062020

Androgen Hormones in PMDD

CompletedPH IVWeill Medical College of Cornell Universityn=1152011

Active, not recruitingPH IIIKey trialNRG Oncologyn=2,7532033

Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer

RecruitingPH IIIKey trialSWOG Cancer Research Networkn=1,2732031

Recent completions

Trials that read out recently, adding to the completed evidence base.

Phase II-III Trial of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prostatectomy With or Without Adjuvant Docetaxel

CompletedPH II/IIINRG Oncologyn=6122025

A Phase III Prospective Randomized Trial of Dose-Escalated Radiotherapy With or Without Short-Term Androgen Deprivation Therapy for Patients With Intermediate-Risk Prostate Cancer

CompletedPH IIIKey trialRadiation Therapy Oncology Groupn=1,5382025

Randomized Trial Assessing Induction of Double Strand Breaks With Androgen Receptor Partial Agonist in Patients on Androgen Suppression

CompletedPH ISidney Kimmel Comprehensive Cancer Center at Johns Hopkinsn=252025

An Open, Randomized, Long-Term Clinical Trial of Flutamide, Testolactone, and Reduced Hydrocortisone Dose vs. Conventional Treatment of Children With Congenital Adrenal Hyperplasia

CompletedPH IIIEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)n=662024

Androgen Excess as a Cause for Adipogenic Dysfunction in PCOS Women

CompletedPH IIUniversity of California, Los Angelesn=232023

A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer

CompletedPH IIIKey trialRadiation Therapy Oncology Groupn=1,5792022

Research activity

1 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Most influential

Radiotherapy and short-term androgen deprivation for localized prostate cancer.

The New England journal of medicine · 2011 · 488 cites